Scott Ullem Sells 13,000 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) CFO Scott Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at $3,371,239.08. This trade represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Edwards Lifesciences Stock Down 0.8%

NYSE:EW traded down $0.70 during trading hours on Wednesday, hitting $85.08. The stock had a trading volume of 4,313,490 shares, compared to its average volume of 4,632,605. The company has a market cap of $49.42 billion, a PE ratio of 46.49, a price-to-earnings-growth ratio of 2.20 and a beta of 0.93. The business has a 50 day simple moving average of $82.50 and a two-hundred day simple moving average of $81.52. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently modified their holdings of EW. Norges Bank bought a new stake in Edwards Lifesciences in the fourth quarter valued at about $803,686,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in Edwards Lifesciences by 111.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after buying an additional 4,805,819 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. Marshall Wace LLP grew its position in shares of Edwards Lifesciences by 127.5% in the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after acquiring an additional 3,864,908 shares in the last quarter. Finally, Viking Global Investors LP bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $238,688,000. Institutional investors own 79.46% of the company’s stock.

More Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Brokerages give EW an above-average stance — the stock received an average rating of “Moderate Buy,” which supports investor conviction and can attract demand. Edwards Lifesciences Receives Average Rating of Moderate Buy
• Positive Sentiment: Equity-research / retail-content pieces list EW among medical-instruments stocks with short-term upside (citing product pipeline, AI/technology tailwinds and M&A/innovation themes), which can draw momentum buyers and ETF/sector flows. 5 Medical Instruments Stocks to Buy (Zacks)
• Neutral Sentiment: Management presented at the Leerink Global Healthcare Conference — transcript available; these presentations typically reiterate strategy, product updates and address analyst questions but did not contain headline surprises that would immediately re-rate the stock. Leerink Conference Transcript
• Neutral Sentiment: Management also presented at Barclays’ Global Healthcare Conference (transcript posted). Conference transcripts can provide useful color on valve/TAVR trends and margin cadence but usually drive gradual re-rating rather than same-day spikes. Barclays Conference Transcript
• Negative Sentiment: Short interest rose sharply in February — shorted shares increased ~56.6% to ~12.38M (about 2.1% of shares outstanding) with a short-interest ratio ~2.7 days. That surge in bearish positioning can amplify downward moves and increase selling pressure on headline weakness.

Wall Street Analyst Weigh In

A number of research firms have weighed in on EW. UBS Group reissued a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Royal Bank Of Canada boosted their price target on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, December 5th. TD Cowen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Piper Sandler restated an “overweight” rating and set a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, Canaccord Genuity Group set a $87.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, December 17th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $96.14.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.